Zebisch A - Search Results

1

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R. Pleyer L, et al. Among authors: zebisch a. Int J Mol Sci. 2017 Feb 15;18(2):415. doi: 10.3390/ijms18020415. Int J Mol Sci. 2017. PMID: 28212292 Free PMC article.

2

Therapy-related leukemia cutis: case study of an aggressive disorder.

Zebisch A, Cerroni L, Beham-Schmid C, Sill H. Zebisch A, et al. Ann Hematol. 2003 Nov;82(11):705-7. doi: 10.1007/s00277-003-0717-y. Epub 2003 Aug 14. Ann Hematol. 2003. PMID: 12920571

3

High expression of the sister-chromatid separation regulator and proto-oncogene hSecurin occurs in a subset of myeloid leukaemias but is not implicated in the pathogenesis of aneuploidy.

Auner HW, Zebisch A, Schimek MG, Bodner C, Hiden K, Linkesch W, Haas OA, Beham-Schmid C, Sill H. Auner HW, et al. Among authors: zebisch a. Leukemia. 2004 Feb;18(2):303-8. doi: 10.1038/sj.leu.2403235. Leukemia. 2004. PMID: 14671639

4

Bedside RNA stabilizing kit systems for gene expression analysis of acute leukemias: influence of non-neoplastic white blood cells.

Zebisch A, Linkesch W, Sill H. Zebisch A, et al. Leukemia. 2005 Jan;19(1):136-7. doi: 10.1038/sj.leu.2403581. Leukemia. 2005. PMID: 15510197 No abstract available.

5

Bedside RNA stabilizing kit systems for gene expression analysis of acute leukemias: influence of non-neoplastic white blood cells.

Zebisch A, Linkesch W, Sill H. Zebisch A, et al. Leukemia. 2005 Apr;19(4):685. doi: 10.1038/sj.leu.2403713. Leukemia. 2005. PMID: 15861178 No abstract available.

6

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.

Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H. Zebisch A, et al. Cancer Res. 2006 Apr 1;66(7):3401-8. doi: 10.1158/0008-5472.CAN-05-0115. Cancer Res. 2006. PMID: 16585161

7

Signaling through RAS-RAF-MEK-ERK: from basics to bedside.

Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J. Zebisch A, et al. Curr Med Chem. 2007;14(5):601-23. doi: 10.2174/092986707780059670. Curr Med Chem. 2007. PMID: 17346150 Review.

8

Are mouthwashes a reliable source of constitutional DNA in patients with leukemia?

Zebisch A, Sill H. Zebisch A, et al. Leuk Res. 2008 Jul;32(7):1164-5. doi: 10.1016/j.leukres.2007.11.003. Epub 2007 Dec 21. Leuk Res. 2008. PMID: 18082258 No abstract available.

9

Severe hemolysis as presenting sign of acute erythroleukemia.

Zebisch A, Sill H. Zebisch A, et al. J Clin Oncol. 2008 Jan 10;26(2):330-1. doi: 10.1200/JCO.2007.14.1481. J Clin Oncol. 2008. PMID: 18182675 No abstract available.

10

Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.

Zebisch A, Haller M, Hiden K, Goebel T, Hoefler G, Troppmair J, Sill H. Zebisch A, et al. Leukemia. 2009 Jun;23(6):1049-53. doi: 10.1038/leu.2009.68. Epub 2009 Apr 9. Leukemia. 2009. PMID: 19357705

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page